Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Maio

Showing results (261-270 of 418) with videos related to

Pageof 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
The Lancet Regional Health. Europe|March 13, 2024
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspectiveIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesotheliomaJoanna Kopecka, Iris C Salaroglio, Luisella Righi, et al.
Cancers|August 14, 2020
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective ExperienceValentina Tuninetti, Marilena Di Napoli, Eleonora Ghisoni, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Tumori|October 18, 2025
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia MedicaAnna Amela Valsecchi, Matilde Scaldaferri, Marcello Tiseo, et al.
Journal of Translational Medicine|July 31, 2024
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)Fabrizio Citarella, Kazuki Takada, Priscilla Cascetta, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Breast (Edinburgh, Scotland)|June 17, 2020
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)Laura Orlando, Vito Lorusso, Francesco Giotta, et al.
Orphanet Journal of Rare Diseases|August 14, 2025
6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal<sup>®</sup>) in primary distal renal tubular acidosisAurélia Bertholet-Thomas, Aurélie De Mul, Julie Bernardor, et al.
Pageof 42

Showing results (261-270 of 418) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
The Lancet Regional Health. Europe|March 13, 2024
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspectiveIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesotheliomaJoanna Kopecka, Iris C Salaroglio, Luisella Righi, et al.
Cancers|August 14, 2020
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective ExperienceValentina Tuninetti, Marilena Di Napoli, Eleonora Ghisoni, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Tumori|October 18, 2025
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia MedicaAnna Amela Valsecchi, Matilde Scaldaferri, Marcello Tiseo, et al.
Journal of Translational Medicine|July 31, 2024
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)Fabrizio Citarella, Kazuki Takada, Priscilla Cascetta, et al.
Clinical Lung Cancer|November 21, 2017
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung CancerElisa Gobbini, Sara Pilotto, Giulia Pasello, et al.
Breast (Edinburgh, Scotland)|June 17, 2020
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)Laura Orlando, Vito Lorusso, Francesco Giotta, et al.
Orphanet Journal of Rare Diseases|August 14, 2025
6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal<sup>®</sup>) in primary distal renal tubular acidosisAurélia Bertholet-Thomas, Aurélie De Mul, Julie Bernardor, et al.
Pageof 42